XML 100 R27.htm IDEA: XBRL DOCUMENT
v2.4.0.8

19. Subsequent Events | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2014 | Dec. 31, 2013
Subsequent Events [Abstract] |  |
NOTE 19 - Subsequent Events | Completed Financings with Net Proceeds of $31,250,466 On April 29, 2014, the Company closed the initial round of a private placement in the aggregate sum of $11,106,000 of a private placement resulting in $9,222,900 of net proceeds after payment of fees, expenses and certain accounts payable. On May 6, 2014, the Company closed the second round of this private placement in the aggregate sum of $13,672,500 resulting in $12,305,250 of net proceeds after payment of fees and certain accounts payable. On May 21, 2014, the Company closed the third round of this private placement in the aggregate sum of $3,489,240 resulting in $3,140,316 of net proceeds after payment of fees. On June 13, 2014, the Company closed the fourth round of this private placement in the aggregate sum of $7,115,000 resulting in $6,403,000 of net proceeds after payment of fees. On July 10, 2014, the Company closed a fifth round of this private placement in the aggregate sum of $200,000 resulting in $179,500 of net proceeds after payment of fees. However, given the Company’s plans to grow its existing businesses and potentially pursue acquisitions, this funding may not be sufficient and the Company may need to raise additional capital in the future to fully implement its business plan. The following is a summary of these five rounds of financing (amounts presented in thousands (000s) except per share amounts):
|  |  | First Round April 29, 2014 |  |  |  | Second Round May 6, 2014 |  |  |  | Third Round May 21, 2014 |  |  |  | Fourth Round June 13, 2014 |  |  |  | Fifth Round July 10, 2014 |  |  |  | Total |
Shares sold |  |  | 2,777 |  |  |  | 3,418 |  |  |  | 872 |  |  |  | 1,779 |  |  |  | 50 |  |  |  | 8,896 |
Price per share |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |
Gross Proceeds |  | $ | 11,106 |  |  | $ | 13,673 |  |  | $ | 3,489 |  |  | $ | 7,115 |  |  | $ | 200 |  |  | $ | 35,583 |
Fees, expenses and payment of certain accounts payable |  |  | (1,883 | ) |  |  | (1,367 | ) |  |  | (349 | ) |  |  | (712 | ) |  |  | (21 | ) |  |  | (4,332 | )
Net proceeds |  | $ | 9,223 |  |  | $ | 12,305 |  |  | $ | 3,140 |  |  | $ | 6,403 |  |  | $ | 180 |  |  | $ | 31,250 |
Warrants issued |  |  | 1,110.60 |  | (a) |  | 1,367.25 |  | (b) |  | 348.92 |  | (c) |  | 711.50 |  | (d) |  | 20 |  | (e) |  | 3,558 |
Strike price of warrants |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |
(a) | Includes warrants to purchase 832,950 shares of common stock issued with the financing and warrants to purchase 277,650 shares of common stock issued to the placement agent.
(b) | Includes warrants to purchase 1,025,438 shares of common stock issued with the financing and warrants to purchase 341,813 shares of common stock issued to the placement agent.
(c) | Includes warrants to purchase 261,693 shares of common stock issued with the financing and warrants to purchase 87,231 shares of common stock issued to the placement agent.
(d) | Includes warrants to purchase 533,625 shares of common stock issued with the financing and warrants to purchase 177,875 shares of common stock issued to the placement agent.
(e) | Includes warrants to purchase 15,000 shares of common stock issued with the financing and warrants to purchase 5,000 shares of common stock issued to the placement agent.
The purchasers of Common Stock received warrants to purchase three shares of Common Stock for every ten shares of Common Stock such Investors purchased in the Private Placement at a strike price of $4.80. The purchase price of each share of Common Stock was $4.00, which was minimum price under the terms of the Private Placement and approximated the volume weighted average market price for ten days prior to the close. The following pro forma financial information has been prepared as if the above financings had occurred on March 31, 2014. The information in these pro forma financials for RestorGenex has been derived from the unaudited balance sheets as of March 31, 2014 and the information presented above on the financings. RestorGenex Corporation Pro Forma Balance Sheets March 31, 2014
|  | March 31, 2014 (a) |
|  |  |  |  | Pro Forma |  |  | Pro Forma |
|  | As Reported |  |  | Adjustments |  |  | Adjusted |
ASSETS |  |  |  |  |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |  |  |  |  |
Cash and equivalents |  | $ | 222,071 |  |  |  | 31,250,466 | (b) |  | $ | 31,472,537 |
Prepaid expenses and deposits |  |  | 2,455,881 |  |  |  | – |  |  |  | 2,455,881 |
Total current assets |  |  | 2,677,952 |  |  |  | 31,250,466 |  |  |  | 33,928,418 |
Property and equipment, net |  |  | 81,563 |  |  |  | – |  |  |  | 81,563 |
Intangible assets |  |  | 9,725,258 |  |  |  | – |  |  |  | 9,725,258 |
Goodwill |  |  | 13,962,880 |  |  |  | – |  |  |  | 13,962,880 |
Total assets |  | $ | 26,447,653 |  |  | $ | 31,250,466 |  |  | $ | 57,698,119 |
LIABILITIES AND SHAREHOLDERS' EQUITY |  |  |  |  |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,601,721 |  |  | $ | – |  |  | $ | 1,601,721 |
Deferred salary |  |  | 838,476 |  |  |  | – |  |  |  | 838,476 |
Accrued interest |  |  | 633,961 |  |  |  | – |  |  |  | 633,961 |
Other accrued expenses and liabilities |  |  | 1,829,119 |  |  |  | – |  |  |  | 1,829,119 |
Payable to officer and former officer |  |  | 156,358 |  |  |  | – |  |  |  | 156,358 |
Rent liability for facilities no longer occupied |  |  | 1,121,495 |  |  |  | – |  |  |  | 1,121,495 |
Notes payable |  |  | 2,932,002 |  |  |  | – |  |  |  | 2,932,002 |
Obligation to issue stock for transfer of liabilities |  |  | 1,581,641 |  |  |  | – |  |  |  | 1,581,641 |
Total current liabilities |  |  | 10,694,773 |  |  |  | – |  |  |  | 10,694,773 |
Long-term liability - deferred taxes on acquisition |  |  | 3,538,051 |  |  |  | – |  |  |  | 3,538,051 |
Commitments and contingencies |  |  |  |  |  |  |  |  |  |  |  |
Shareholders' equity |  |  |  |  |  |  |  |  |  |  |  |
Series C 10% Preferred Stock, $0.001 par value: 1,000,000 shares authorized, 0 shares issued and outstanding |  |  | – |  |  |  | – |  |  |  | – |
Series D 10% Preferred Stock, $0.001 par value: 500,000 shares authorized, 0 shares issued and outstanding |  |  | – |  |  |  | – |  |  |  | – |
Series E 5% Preferred Stock, $0.001 par value: 10,000 shares authorized; 0 shares issued and outstanding |  |  | – |  |  |  | – |  |  |  | – |
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 8,683,785 shares issued and outstanding |  |  | 8,684 |  |  |  | 8,896 | (c) |  |  | 17,580 |
Additional paid-in capital |  |  | 74,670,219 |  |  |  | 31,241,570 | (d) |  |  | 105,911,789 |
Accumulated deficit |  |  | (62,464,074 | ) |  |  | – |  |  |  | (62,464,074 | )
Total shareholders' equity |  |  | 12,214,829 |  |  |  | 31,250,466 |  |  |  | 43,465,295 |
Total liabilities and shareholders' equity |  | $ | 26,447,653 |  |  | $ | 31,250,466 |  |  | $ | 57,698,119 |
(a) | Assumes the financings occurred on March 31, 2014
(b) | Net cash proceeds to the Company from financings
(c) | Value of 8,895,685 shares sold in the financings at a par value of $0.001
(d) | Difference between net cash proceeds and value of shares sold
Issuance of Note In April 2014, the Company agreed to issue to our law firm a non-interest bearing convertible note in the aggregate principal amount of $875,000 (the “Note”) as payment in full for the amounts owed to them at that time, contingent on the Company successfully concluding a Cash Proceeds Event, including the $467,200 note that was issued on July 1, 2012. The Note was due in full on March 31, 2015. Based on the terms of the Note, on May 6, 2014 the Company repaid the note in full upon the receipt of the $21,528,150 in funding mentioned above. As part of this settlement, the Company also agreed to issue to the holder of the Note 53,457 shares of the Company’s Common Stock sold in the Offering. The holder will be entitled to the same registration and other rights with respect to such securities as are granted to the purchasers of securities in the Offering. Settlement of Amounts Owed After March 31, 2014, the Company has reached a number of settlements with vendors, former directors and employees whereby $875,000 of liabilities were settled for $225,000 in cash and the issuance of 160,000 shares of common stock valued at $870,000 at the market price on the date of the settlement for total consideration of $1,095,000, resulting in a loss on settling these liabilities of $220,000. The Company is currently in negotiations with other vendors, former directors and employees to reduce the amounts owed to them and use a combination of stock and cash to settle these reduced amounts, but there can be no assurance that the Company will be successful in doing so, or that such settlements will amount to a material reduction in the amounts owed to these vendors, former directors and employees, or that these negotiations will not result in further losses. | Reverse Split and Name Change On March 7, 2014, the Company effected a reverse stock split of 1 to 100 with respect to its Common Stock and the Company changed its corporate name from Stratus Media Group, Inc. to RestorGenex Corporation, a biopharmaceutical company. All stock numbers herein are post reverse split. Issuance of Note and Settlement of Amounts Owed (Unaudited) In April 2014, the Company agreed to issue to our law firm a non-interest bearing convertible note in the aggregate principal amount of $875,000 (the “Note”) as payment in full for the amounts owed to them at that time, contingent on the Company successfully concluding a Cash Proceeds Event, including the $467,200 note that was issued on July 1, 2012. The Note is due in full on March 31, 2015, provided that the Company is required to prepay (i) $1.00 in principal amount of the Note for each $15.00 raised by the Company in all Cash Proceeds Events (as defined in the Note), up to the first $7.5 million raised, for total repayments of up to $500,000; (b) an additional $100,000 in principal amount of the Note when the cumulative amounts so raised in all Cash Proceeds Events equal $10.0 million; and (c) the balance due under the Note when the cumulative amounts so raised in all Cash Proceeds Events equal $12.5 million. The Note also provides that the holder may, at its option, convert all or any portion of the outstanding balance thereunder into the securities issued and sold in certain securities offerings by the Company, including the offering currently underway by the Company (the “Offering”). In connection with the issuance of the Note, the Company also agreed to issue to the holder of the Note, for no additional consideration, $213,827 worth of the Company’s securities sold in the Offering (valued at the offering price of the securities) upon the closing of the Offering. The holder will be entitled to the same registration and other rights with respect to such securities as are granted to the purchasers of securities in the Offering. In the event that the Company does not repay at least $500,000 principal amount of the Note by July 1, 2014, the Note will be deemed to be in default and will automatically convert into a non-convertible note in the principal amount of $1,188,827, which note will bear interest at the annual rate of 10% and be due and payable upon demand. The Company is currently in negotiations with other vendors, former directors and employees to reduce the amounts owed to them and use a combination of stock and cash to settle these reduced amounts, but there can be no assurance that the Company will be successful in doing so or that such settlements will amount to a material reduction in the amounts owed to these vendors, former directors and employees. Acquisitions On March 28, 2014, the Company acquired Paloma Pharmaceuticals, Inc. (“Paloma”) for consideration of 2,500,000 shares of common stock and VasculoMedics, Inc. (“VasculoMedics”) for consideration of 220,000 shares of common stock. In connection with the acquisition of Paloma, the Company agreed to assume three promissory notes which have been extended to a maturity date of March 28, 2015. The notes have a current balance (principal and interest) of approximately $1,132,000. 20(b). Subsequent Event (Unaudited) Completed Financings with Net Proceeds of $31,250,466 On April 29, 2014, the Company closed the initial round of a private placement in the aggregate sum of $11,106,000 of a private placement resulting in $9,222,900 of net proceeds after payment of fees, expenses and certain accounts payable. On May 6, 2014, the Company closed the second round of this private placement in the aggregate sum of $13,672,500 resulting in $12,305,250 of net proceeds after payment of fees and certain accounts payable. On May 21, 2014, the Company closed the third round of this private placement in the aggregate sum of $3,489,240 resulting in $3,140,316 of net proceeds after payment of fees. On June 13, 2014, the Company closed the fourth round of this private placement in the aggregate sum of $7,115,000 resulting in $6,403,000 of net proceeds after payment of fees. On July 10, 2014, the Company closed a fifth round of this private placement in the aggregate sum of $200,000 resulting in $179,500 of net proceeds after payment of fees. However, given the Company’s plans to grow its existing businesses and potentially pursue acquisitions, this funding may not be sufficient and the Company may need to raise additional capital in the future to fully implement its business plan. The following is a summary of these five rounds of financing (amounts presented in thousands (000s) except per share amounts):
|  |  | First Round April 29, 2014 |  |  |  | Second Round May 6, 2014 |  |  |  | Third Round May 21, 2014 |  |  |  | Fourth Round June 13, 2014 |  |  |  | Fifth Round July 10, 2014 |  |  |  | Total |
Shares sold |  |  | 2,777 |  |  |  | 3,418 |  |  |  | 872 |  |  |  | 1,779 |  |  |  | 50 |  |  |  | 8,896 |
Price per share |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |  |  | $ | 4.00 |
Gross Proceeds |  | $ | 11,106 |  |  | $ | 13,673 |  |  | $ | 3,489 |  |  | $ | 7,115 |  |  | $ | 200 |  |  | $ | 35,583 |
Fees, expenses and payment of certain accounts payable |  |  | (1,883 | ) |  |  | (1,367 | ) |  |  | (349 | ) |  |  | (712 | ) |  |  | (21 | ) |  |  | (4,332 | )
Net proceeds |  | $ | 9,223 |  |  | $ | 12,305 |  |  | $ | 3,140 |  |  | $ | 6,403 |  |  | $ | 180 |  |  | $ | 31,250 |
Warrants issued |  |  | 1,110.60 |  | (a) |  | 1,367.25 |  | (b) |  | 348.92 |  | (c) |  | 711.50 |  | (d) |  | 20 |  | (e) |  | 3,558 |
Strike price of warrants |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |  |  | $ | 4.80 |
(a) | Includes warrants to purchase 832,950 shares of common stock issued with the financing and warrants to purchase 277,650 shares of common stock issued to the placement agent.
(b) | Includes warrants to purchase 1,025,438 shares of common stock issued with the financing and warrants to purchase 341,813 shares of common stock issued to the placement agent.
(c) | Includes warrants to purchase 261,693 shares of common stock issued with the financing and warrants to purchase 87,231 shares of common stock issued to the placement agent.
(d) | Includes warrants to purchase 533,625 shares of common stock issued with the financing and warrants to purchase 177,875 shares of common stock issued to the placement agent.
(e) | Includes warrants to purchase 15,000 shares of common stock issued with the financing and warrants to purchase 5,000 shares of common stock issued to the placement agent.
The purchasers of Common Stock received warrants to purchase three shares of Common Stock for every ten shares of Common Stock such Investors purchased in the Private Placement at a strike price of $4.80. The purchase price of each share of Common Stock was $4.00, which was minimum price under the terms of the Private Placement and approximated the volume weighted average market price for ten days prior to the close. RESTORGENEX CORPORATION CONSOLIDATED BALANCE SHEETS
|  | March 31, |  |  | December 31, |
|  | 2014 |  |  | 2013 |
|  | (Unaudited) |  |  |  |
ASSETS |  |  |  |  |  |  |  |
Current assets |  |  |  |  |  |  |  |
Cash and equivalents |  | $ | 222,071 |  |  | $ | 254,964 |
Prepaid expenses and deposits |  |  | 2,455,881 |  |  |  | 2,743,319 |
Total current assets |  |  | 2,677,952 |  |  |  | 2,998,283 |
Property and equipment, net |  |  | 81,563 |  |  |  | 11,262 |
Intangible assets |  |  | 9,725,258 |  |  |  | 7,691,682 |
Goodwill |  |  | 13,962,880 |  |  |  | 7,642,825 |
Total assets |  | $ | 26,447,653 |  |  | $ | 18,344,052 |
LIABILITIES AND SHAREHOLDERS' EQUITY |  |  |  |  |  |  |  |
Current liabilities |  |  |  |  |  |  |  |
Accounts payable |  | $ | 1,601,721 |  |  | $ | 1,520,206 |
Deferred salary |  |  | 838,476 |  |  |  | 571,328 |
Accrued interest |  |  | 633,961 |  |  |  | 89,472 |
Other accrued expenses and liabilities |  |  | 1,829,119 |  |  |  | 1,697,714 |
Payable to officer |  |  | 156,358 |  |  |  | 156,358 |
Rent liability for facilities no longer occupied |  |  | 1,121,495 |  |  |  | 1,121,495 |
Notes payable |  |  | 2,932,002 |  |  |  | 1,867,002 |
Obligation to issue stock for transfer of liabilities |  |  | 1,581,641 |  |  |  | 1,854,743 |
Total current liabilities |  |  | 10,694,773 |  |  |  | 8,878,318 |
Long-term liability - deferred taxes on acquisition |  |  | 3,538,051 |  |  |  | 3,000,576 |
Commitments and contingencies |  |  |  |  |  |  |  |
Shareholders' equity |  |  |  |  |  |  |  |
Series C 10% Preferred Stock, $0.001 par value: 1,000,000 shares authorized, 0 and 0 shares issued and outstanding |  |  | – |  |  |  | – |
Series D 10% Preferred Stock, $0.001 par value: 500,000 shares authorized, 0 and 0 shares issued and outstanding |  |  | – |  |  |  | – |
Series E 5% Preferred Stock, $0.001 par value: 10,000 shares authorized; 0 and 0 shares issued and outstanding |  |  | – |  |  |  | – |
Common stock, $0.001 par value: 1,000,000,000 shares authorized; 8,683,785 and 5,813,785 shares issued and outstanding |  |  | 8,684 |  |  |  | 5,814 |
Additional paid-in capital |  |  | 74,670,219 |  |  |  | 67,390,493 |
Accumulated deficit |  |  | (62,464,074 | ) |  |  | (60,937,550 | )
Total RestorGenex shareholders' equity |  |  | 12,214,829 |  |  |  | 6,458,757 |
Non-controlling interest equity |  |  | – |  |  |  | 6,401 |
Total shareholders' equity |  |  | 12,214,829 |  |  |  | 6,465,158 |
Total liabilities and shareholders' equity |  | $ | 26,447,653 |  |  | $ | 18,344,052 |
See accompanying Notes to Financial Statements. RESTORGENEX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
|  | Three Months Ended March 31, |
|  | 2014 |  |  | 2013 |
Revenues |  | $ | – |  |  | $ | – |
Cost of revenues |  |  | – |  |  |  | – |
Gross margin |  |  | – |  |  |  | – |
Operating expenses |  |  |  |  |  |  |  |
General and administrative |  |  | 611,845 |  |  |  | 624,674 |
Warrants, options and stock compensation |  |  | 149,885 |  |  |  | 1,316,148 |
Legal and professional services |  |  | 131,686 |  |  |  | 143,103 |
Depreciation and amortization |  |  | 478,104 |  |  |  | 8,687 |
Total operating expenses |  |  | 1,371,520 |  |  |  | 2,092,612 |
Loss from operations |  |  | (1,371,520 | ) |  |  | (2,092,612 | )
Other (income)/expenses |  |  |  |  |  |  |  |
Loss on adjustments to fair value of derivative liability |  |  | – |  |  |  | 236,850 |
Other income |  |  | (49,639 | ) |  |  | (2,564 | )
Interest expense |  |  | 58,294 |  |  |  | 22,971 |
Total other expenses |  |  | 8,655 |  |  |  | 257,257 |
Net loss from continuing operations |  |  | (1,380,175 | ) |  |  | (2,349,869 | )
Net loss from discontinued operations |  |  | – |  |  |  | (126,911 | )
Net loss |  |  | (1,380,175 | ) |  |  | (2,476,780 | )
Preferred dividends |  |  | – |  |  |  | 124,375 |
Net loss attributable to holders of RestorGenex Corporation common stock |  | $ | (1,380,175 | ) |  | $ | (2,601,155 | )
Basic and diluted loss per share for continuing operations |  | $ | (0.23 | ) |  | $ | (2.77 | )
Basic and diluted loss per share for discontinued operations |  |  | – |  |  |  | (0.14 | )
Total basic and diluted loss per share |  | $ | (0.23 | ) |  | $ | (2.91 | )
Basic weighted average shares outstanding |  |  | 5,934,474 |  |  |  | 892,534 |
Fully-diluted weighted average shares outstanding |  |  | 5,934,474 |  |  |  | 1,207,534 |
See accompanying Notes to Financial Statements. RESTORGENEX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
|  | Three Months Ended March 31, |
|  | 2014 |  |  | 2013 |
Cash flows from operating activities: |  |  |  |  |  |  |  |
Net loss from continuing operations |  | $ | (1,380,175 | ) |  | $ | (2,349,869 | )
Adjustments to reconcile net loss to net cash used in operating activities: |  |  |  |  |  |  |  |
Depreciation and amortization |  |  | 478,104 |  |  |  | 8,687 |
Gain on adjustments to fair value of derivative liability |  |  | – |  |  |  | 236,850 |
Warrants, options and stock |  |  | 149,885 |  |  |  | 1,323,098 |
Stock issued for services |  |  | – |  |  |  | 130,000 |
Increase / (decrease) in: |  |  |  |  |  |  |  |
Prepaid expenses and deposits |  |  | – |  |  |  | (36,100 | )
Accounts payable |  |  | 81,515 |  |  |  | (17,672 | )
Deferred salary |  |  | 267,148 |  |  |  | 181,555 |
Accrued interest |  |  | 58,294 |  |  |  | 22,975 |
Other accrued expenses and liabilities |  |  | (87,664 | ) |  |  | 194,293 |
Net cash used in operating activities |  |  | (432,893 | ) |  |  | (306,183 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |
Proceeds from notes payable |  |  | 400,000 |  |  |  | 200,000 |
Net cash provided by financing activities |  |  | 400,000 |  |  |  | 200,000 |
Decrease in cash and equivalents from continuing operations |  |  | (32,893 | ) |  |  | (106,183 | )
Decrease in cash and equivalents from discontinued operations |  |  | – |  |  |  | (94,475 | )
Total decrease in cash and equivalents |  |  | (32,893 | ) |  |  | (200,658 | )
Cash and equivalents, beginning of period |  |  | 254,964 |  |  |  | 312,093 |
Cash and equivalents, end of period |  | $ | 222,071 |  |  | $ | 111,435 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |  |  |
Cash paid during the period for interest |  | $ | – |  |  | $ | – |
Cash paid during the period for income taxes |  | $ | – |  |  | $ | – |
See accompanying Notes to Financial Statements.

X
- Details
Name: | us-gaap_SubsequentEventsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + References No definition available. + Details
Name: | us-gaap_SubsequentEventsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration